Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for ≥ 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial
ConclusionA substantial (22.7%) number of guselkumab-treated patients in the VOYAGE 1 clinical trial maintained complete skin clearance for a consecutive period of ≥ 156 weeks. Factors associated with this outcome may suggest clinical benefits of holistic treatment approaches.Trial RegistrationNCT02207231.
Source: American Journal of Clinical Dermatology - Category: Dermatology Source Type: research
More News: Arthritis | Clinical Trials | Dermatology | Diabetes | Eating Disorders & Weight Management | Endocrinology | Obesity | Psoriasis | Psoriatic Arthritis | Rheumatology | Skin | Smokers | Statistics